データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
268535-76-8説明Cetus has introduced a stable rDNA interleukin-2 (rIL-2) for the treatment of renal cell carcinoma. Recent studies showed that rIL-2 in combination with lymphokine activated killer cells or tumor infiltrating lymphocytes induced regression or partial regression in patients with advanced metastatic cancers.
定義A type of biological response modifier (a substance that can improve the body’s natural response to disease). It stimulates the growth of certain disease-fighting blood cells in the immune system. Also called IL-2.